OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in HIV and AIDS is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Editorial introductions	47
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	36
Future options for long-acting HIV treatment and prevention	34
Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research	33
The sounds of silencing: dynamic epigenetic control of HIV latency	31
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	30
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	27
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure	26
Editorial introductions	25
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	24
Harnessing natural killer cells to target HIV-1 persistence	24
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	23
Editorial introduction	23
New latency-promoting agents for a block-and-lock functional cure strategy	22
Editorial introduction	20
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	19
Pulse check: modern strategies for cardiovascular risk in women with detection and prevention in women with HIV	18
The double burden: navigating HIV co-infections with HCV, HBV, and Mtb	17
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	16
Editorial introduction	15
Persistent elite controllers as the key model to identify permanent HIV remission	15
Loneliness and social isolation in people with HIV	15
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	15
Challenges towards an AIDS-free generation in Africa and Asia	14
Public health surveillance and outbreak preparedness for mpox	14

Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	14
Estrogen depletion and immune activation and inflammation in women with HIV	14
Balancing polypharmacy and comorbidity management: cardiovascular health	13
Impact of coronavirus disease 2019 on co-morbidities in HIV	13
The origins of new SARS-COV-2 variants in immunocompromised individuals	13
Defining multimorbidity in people with HIV – what matters most?	13
New vector and vaccine platforms: mRNA, DNA, viral vectors	13
Stigma as a facilitator of the 2022 mpox outbreak	13
Editorial introduction	13
The multifaceted nature of HIV tissue reservoirs	12
Role of follicular homing natural killer cells in HIV infection	12
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	12
Mpox and the impact on people with HIV	12
Aging of adult lifetime survivors with perinatal HIV	12
Viral and immune predictors of HIV posttreatment control	12
Integrating substance use services into HIV care: an underused implementation science opportunity	12
Gender and sex considerations in HIV and bone health	11
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	10
Single-cell sequencing technologies: a multiomics toolbox for investigating HIV-1 persistence	10
Broadly neutralizing antibodies for HIV treatment and cure approaches	10
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	10
Metabolic dysfunction-associated steatotic liver disease in people with HIV	10
Obesity among women with HIV	10
Roadmap for spatial transcriptomics of HIV in tissues	10
Use of implementation theories, models, and frameworks in PrEP implementation research from 2022–2025: innovation and participation	9
HIV and cardiovascular disease: the role of inflammation	9
Maintain the gains: methods to evaluate the sustainability and scalability of HIV-related prevention, care, and treatment programs	9
The severity of COVID-19 across the spectrum of HIV	9
Host factors predisposing to kidney disease in people with HIV	9
Editorial introductions	8
HIV drug resistance in various body compartments	8
Editorial introduction	8
Editorial introductions	8
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	8
Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance	8
Causes and outcomes of hepatic fibrosis in persons living with HIV	7
Editorial: Is it time to implement injectable antiretroviral treatments globally?	7
Mpox in 2026: what we knew, what we have learned, and what we still have to learn	7
Innovative models of care supporting people aging with HIV	7
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
Editorial introductions	7
Persistent HIV-1 transcription during ART: time to reassess its significance?	7
Strategies to target the central nervous system HIV reservoir	7
The pathogenesis of obesity in people living with HIV	7
Innate immune mechanisms in HIV elite controllers	6
Whole person HIV services: a social science approach	6
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	6
The role of analytical treatment interruptions in shaping HIV-specific immunity and HIV cure	6
HIV-1 subtypes and latent reservoirs	6
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	6

Evaluating immunotherapy as a pathway toward HIV cure	6
Hepatitis C elimination in people with HIV: progress, gaps, and future directions	6
Editorial introductions	6
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	6
What can spontaneous controllers, posttreatment controllers and postintervention controllers teach us about an HIV cure?	6
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	6
Contemporary issues in gynecologic and reproductive health for women with HIV	6
Promoting patient-centered care within HIV care settings in sub-Saharan Africa	5
Role of islatravir in HIV treatment and prevention: an update	5
γc-cytokines in HIV Cure Research	5
Editorial introductions	5
Humanized mice for studying HIV latency and potentially its eradication	5
Towards an HIV cure: one cell at a time	5
Editorial introductions	5
Cardiovascular disease risk in women living with HIV	5
Editorial introductions	5
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	5
Cognitive impairment in persons with HIV: changing aetiologies and management strategies	5
Human papillomavirus infection among adolescents living with HIV: a focus on prevention	5
Scaling up preexposure prophylaxis to maximize HIV prevention impact	5
Single cell analyses of the HIV reservoir in the CNS and CSF: recent insights and implications	5
Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults	5
Care of people aging with HIV in resource limited settings	5
Editorial: HIV and cardiovascular disease: recognizing and reducing disparities	5
It's all in the gut: the central role of the gut and microbiome in preventing disease progression in simian immunodeficiency viruses infected African nonhuman primates	5
Towards a molecular profile of antiretroviral therapy-free HIV remission	5
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?	5
The state of the art of adaptation strategies for HIV-related interventions	4
Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission	4
Editorial introduction	4
Editorial introduction	4
An evidence-based call for tailored interventions to support women with HIV who use substances	4
The female microbiome in HIV prevention, pathogenesis, and treatment	4
The predictive value of macaque models of preexposure prophylaxis for HIV prevention	4
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	4
Delivery platforms for broadly neutralizing antibodies	4
The power of ten in HIV remission: insights from hematopoietic stem cell transplantation	4
Targeting HIV myeloid and central nervous system reservoirs for HIV cure	4
Modeling the fallout: projecting the global impact of donor funding cuts on HIV prevention, treatment, and care	3
Stepping stones to cure in children with HIV	3
Mycobacterium tuberculosis in HIV co-infection: a growing concern in Europe?	3
Understanding residual risk of cardiovascular disease in people with HIV	3
The vaginal microbiome and HIV transmission dynamics	3
HIV T-cell immunogen design and delivery	3
Using single cell technologies to understand HIV latency models	3
Pediatric immunotherapy and HIV control	3
The future of long-acting agents for preexposure prophylaxis	3
Editorial introductions	3
Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV	3
Geriatric syndromes in women living with HIV	3
Pulmonary comorbidities in people with HIV− the microbiome connection	3
HIV and obesity: updates in management strategies	3
Post-intervention control in HIV immunotherapy trials	3
A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment	3
Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions	3
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	3
Monocytes across life span in HIV infection: lights and shadows	3
Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention	3
HIV cure: an acceptability scientific agenda	3
Utilizing immunotherapy towards achieving a functional cure for HIV-1	3
Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development	3
Editorial introductions	3
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection	3
Management of pain and other palliative needs in older people with HIV	3
Zika virus: an overview update	3
Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV	3
Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research	3
Cardiovascular health in people with perinatally acquired HIV – where do we stand?	3